Project Grant R03CA304040
Award Date
7/18/25
Completion Date
6/30/27
Dollars Obligated
$177K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Pensilvania, EE. UU.
Similar Awards
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $571,271 to the University of Texas Health Science Center at Houston to develop a targeted therapy for the treatment of metastatic castration-resistant prostate cancer (MCRPC). The research aims to synthesize a prostate-specific membrane antigen (PSMA)-targeted drug conjugate that can selectively deliver the microtubule inhibitor cryptophycin to MCRPC tumors. The project will...
This $377,870 Project Grant awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports the development and validation of novel synthetic transcriptional repressors (STRs) capable of directly inhibiting the oncogenic transcription factor MYC. The grant aims to: 1) Optimize STR structures for high-affinity and specific binding to MYC target DNA sequences, 2) Enhance cellular and pharmacologic delivery of STRs while mapping their effects on epigenetic and...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $400,000 to Cancer Targeted Technology LLC to develop and validate a novel PSMA-targeted small molecule prodrug called CTT2274 for the treatment of advanced prostate cancer. The key product being developed under this award is CTT2274, which utilizes a unique prodrug delivery mechanism to concentrate the potent tubulin disruptor monomethyl auristatin E (MMAE) selectively within...
This Project Grant award of $371,719 from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) supports research by the University of Pennsylvania to characterize epigenetic targets in prostate cancer. The key objectives are to: Gain mechanistic insights into how the histone methyltransferase NSD2 influences the chromatin landscape to facilitate the assembly of the androgen receptor (AR) enhanceosome complex and enhance AR-driven transcription in prostate cancer...
This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) will support research at Weill Medical College of Cornell University to investigate the role of the androgen receptor (AR) in both normal prostate cell function and prostate cancer development. The $564,543 award, effective March 1, 2025 through February 28, 2030, will enable the research team to determine the factors that mediate the switch between AR's normal, growth-suppressive...
The National Cancer Institute (NCI) awarded a $185,760 Project Grant under the Cancer Research Manpower (CFDA 93.398) program to The Regents of the University of California, San Francisco (UCSF) to develop a novel tumor-targeted combination therapy for metastatic castration-resistant prostate cancer (mCRPC). The project aims to enhance efficacy and reduce toxicity by co-delivering cytotoxic drugs and the radioactive isotope Actinium-225 directly to cancer cells. Key objectives include developing...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $415,902.00 to the University of Massachusetts Boston to conduct research aimed at overcoming lineage plasticity and therapy resistance in castration-resistant prostate cancer. The key research objectives are to determine if expression of the FOXA2 transcription factor drives prostate cancer cells into a multilineage transition state, investigate how FOXA2 collaborates with the AP-1...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $429,123 to Purdue University from April 1, 2025 to March 31, 2030 to develop improved inhibitors that selectively target the CBX8 chromatin reader domain. The goal is to validate the CBX8 chromodomain as a therapeutic target in MLL-AF9 leukemia, by creating CBX8-selective inhibitors with improved cell permeability compared to current probes. The research will utilize DNA-encoded...
This Project Grant award from the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) supports research to define key components of the PRMT5 axis that impair cell viability upon PRMT5 inhibition and identify pathways that can restore viability in MTAP-deleted cancer cells. The $442,089 award to Yale University will leverage a genome-scale CRISPR activation platform to identify genes that modulate sensitivity to PRMT5 pathway inhibition. The research aims to...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to The University of Texas Southwestern Medical Center provides $472,458 to conduct research aimed at overcoming mechanisms of PTPN1 driving therapy- and castration-resistant prostate cancer. The 5-year project, starting December 1, 2024, will investigate the regulation of the PTPN1 gene and its role in the transition of prostate cancer cells to a therapy-resistant neuroendocrine...